Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Profit After Tax (2022 - 2025)

Historic Profit After Tax for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Atara Biotherapeutics' Profit After Tax rose 8035.97% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year increase of 11757.36%. This contributed to the annual value of -$85.4 million for FY2024, which is 6907.1% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Profit After Tax is -$4.3 million, which was up 8035.97% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Profit After Tax ranged from a high of $38.0 million in Q1 2025 and a low of -$88.1 million during Q1 2022
  • In the last 4 years, Atara Biotherapeutics' Profit After Tax had a median value of -$31.8 million in 2024 and averaged -$36.9 million.
  • Per our database at Business Quant, Atara Biotherapeutics' Profit After Tax plummeted by 48507.53% in 2023 and then skyrocketed by 21970.9% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Profit After Tax (Quarter) stood at -$74.6 million in 2022, then increased by 18.94% to -$60.4 million in 2023, then surged by 79.0% to -$12.7 million in 2024, then skyrocketed by 66.1% to -$4.3 million in 2025.
  • Its last three reported values are -$4.3 million in Q3 2025, $2.4 million for Q2 2025, and $38.0 million during Q1 2025.